Revolution Medicines, INC Form 4 insider transactions

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 4,302 shares of common stock to cover tax withholding on RSU vesting.

Revolution Medicines' CEO, Mark A. Goldsmith, sold 12,871 shares of common stock for tax withholding obligations under a pre-arranged 10b5-1 plan.

Revolution Medicines' Chief Operating Officer, Margaret A. Horn, reported a future sale of 4,583 common shares to cover tax withholding obligations related to RSU vesting.

Revolution Medicines CFO Jack Anders sold 2,753 shares of common stock to cover tax withholding on RSU vesting, as per a pre-arranged 10b5-1 plan.

Revolution Medicines' General Counsel, Jeff Cislini, reported sales of common stock totaling 2,958 shares under pre-arranged 10b5-1 plans.

Revolution Medicines' EVP of Clinical Development, Xiaolin Wang, sold 2,010 shares of common stock for $99.4804 each to cover tax withholding from RSU vesting.

Revolution Medicines Director Elizabeth M. Anderson reported gifting 15,000 common shares, transferring direct ownership to an irrevocable trust.

Revolution Medicines' EVP of Clinical Development, Xiaolin Wang, reported the acquisition of common stock and stock options as part of a pre-planned equity grant.

Revolution Medicines' Chief Medical Officer, Wei Lin, acquired 15,100 shares of common stock and 34,000 stock options, effective March 1, 2026.

Revolution Medicines' President of Research and Development, Stephen Michael Kelsey, acquired 21,100 shares of common stock and 47,600 stock options.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and sold a significant number of shares, primarily through a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn was granted 21,100 shares of common stock and options to purchase 47,600 shares.

Revolution Medicines General Counsel Jeff Cislini acquired 14,500 shares of common stock and 32,500 stock options in a pre-planned transaction.

Revolution Medicines' Chief Financial Officer, Jack Anders, was granted 20,200 shares of common stock and 45,400 stock options, effective March 1, 2026.

Revolution Medicines' President and CEO, Mark A. Goldsmith, exercised options to acquire 24,010 shares of common stock at $0.54 per share.

Revolution Medicines' General Counsel, Jeff Cislini, sold 908 shares of common stock for $115.6 per share under a pre-arranged 10b5-1 plan.

Revolution Medicines' Chief Operating Officer, Margaret Horn, reported exercising stock options and selling 75,000 shares of common stock for over $7.5 million under a pre-arranged 10b5-1 trading plan.

Revolution Medicines CFO Jack Anders exercised options and sold 10,000 shares of common stock for $98.00 per share under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,688 shares of common stock at $76.8169 per share to cover tax withholding obligations.

Revolution Medicines CEO Mark A. Goldsmith sold 15,394 shares of common stock to cover tax withholding obligations from RSU vesting.

A Revolution Medicines executive sold 5,447 shares of common stock at $76.8172 per share to cover tax withholding obligations from RSU vesting.

Revolution Medicines' Chief Operating Officer, Margaret A. Horn, sold 4,847 shares of common stock to cover tax withholding obligations related to RSU vesting.

Revolution Medicines' Chief Financial Officer, Jack Anders, sold 3,104 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Revolution Medicines CFO Jack Anders exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold a portion of his common stock holdings, including shares held in trusts, under a 10b5-1 plan.

Revolution Medicines, Inc. CEO Mark A. Goldsmith exercised stock options and subsequently sold 20,000 shares of common stock on November 18, 2025, as part of a pre-arranged 10b5-1 trading plan.

Revolution Medicines General Counsel Jeff Cislini exercised options and sold 13,388 shares of common stock under a pre-arranged 10b5-1 trading plan.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, exercised stock options and sold 10,000 shares of common stock for a significant profit under a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported exercising stock options, selling 30,000 shares, and transferring 100,000 shares to family trusts, all executed under a pre-arranged 10b5-1 trading plan.